NCT07671898 Comparison of Focal Cryoablation vs. Radiofrequency Cardioneuroablation for Bradyarrhythmias
| NCT ID | NCT07671898 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
| Condition | Bradycardia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2027-12-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-09-01 with a primary completion date of 2027-12-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bradyarrhythmias are conditions where the heart beats too slowly, causing symptoms like dizziness, fainting, and fatigue. In some patients, these slow heart rhythms are caused by overactivity of the vagus nerve (the part of the nervous system that slows the heart down). Cardioneuroablation (CNA) is a catheter-based procedure that targets and reduces the effect of these overactive nerves on the heart. It is an alternative to permanent pacemaker implantation, especially for younger patients. Traditionally, CNA is performed using radiofrequency (RF) energy to create small burns in specific areas of the heart. This study investigates whether focal cryoablation (freezing technology using the Freezor™ Xtra catheter) is as safe and effective as standard RF ablation for CNA. This is a prospective, non-randomized study. Participants will receive either RF ablation (N=30) or cryoablation (N=30). The study will evaluate the recurrence of slow heart rhythms and fainting episodes, as well as any complications, over 12 months of follow-up.
Eligibility Criteria
Inclusion Criteria: * Age 18 to 60 years; * Symptomatic bradycardia (sinus bradycardia or bradycardia due to atrioventricular block, including transient); * Severe asymptomatic sinus bradycardia (heart rate less than 30 beats per minute); * Transient second- or third-degree atrioventricular block; * Persistent second-degree atrioventricular block; * Rhythm pauses greater than 6 seconds; * Recurrent syncope or presyncope with documented association with bradycardia (without trauma); * Positive response to atropine (heart rate increase ≥25% from baseline or \>90 beats per minute) OR positive response to exercise (heart rate increase ≥25% from baseline or \>90 beats per minute, OR conversion of second- or third-degree atrioventricular block to first-degree block or complete normalization of atrioventricular conduction during sinus rhythm); Exclusion Criteria: * Chronic antiarrhythmic drug therapy (ongoing); * Presence of implanted pacemaker, cardiac resynchronization therapy device, or implantable cardioverter-defibrillator; * Bradyarrhythmia secondary to medications; * Bradyarrhythmia secondary to electrolyte imbalance (hyperkalemia); * Bradyarrhythmia secondary to hypothyroidism; * Bradyarrhythmia secondary to obstructive sleep apnea syndrome; * Absence of response to pharmacological denervation (no heart rate increase after atropine administration up to maximum dose of 0.2 mg/kg); * Clinically significant coronary artery disease; * Post-myocardial infarction cardiosclerosis; * Hemodynamically significant congenital heart disease (including surgically corrected); * Stable ventricular tachycardia in the setting of bradycardia; * History of stroke or transient ischemic attack; * Prior open-heart surgery; * Prior catheter-based coronary artery intervention or percutaneous coronary intervention; * Pregnancy or breastfeeding; Age less than 18 years Age greater than 60 years
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07671898 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Bradycardia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07671898 currently recruiting?
Yes, NCT07671898 is actively recruiting participants. Contact the research team at romancer@rambler.ru for enrollment information.
Where is the NCT07671898 trial being conducted?
This trial is being conducted at Tomsk, Russia.
Who is sponsoring the NCT07671898 clinical trial?
NCT07671898 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. The trial plans to enroll 60 participants.